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l Introduction
Since the advent of medicamentous suppression of
labor with beta-sympathicomimetics the calcium
antagonist Verapamil** has been universally ad-
ministered to antagonize cardiovascular and sub-
jective side effects.
The administration of adrenergics induces an acti-
vation of the calcium-dependent electromechanical
coupling in the myocardium (Fig. 1). The trans-
membranous calcium influx into the cell increases,
resulting in enhanced activation of the ATP-ases.
This, in turn, leads to increased consumption of
high-energy phosphates, such äs ATP and creatine
phosphate. Due to the accelerated heart rate and
increased tension, the myocardial oxygen con-
sumption rises.
High doses of adrenergics but also protracted treat-
ment with low doses, especially in conjunction
with additional doses of Ca, vitamin D, AT 10 and
cortisone äs well äs with potassium or magnesium
deficiency or with heart disease may involve the
risk of hypoxic necrosis development with the
clinical picture of hypertrophic myocardiopathy
[12].
In addition to general suppression of excitation,
Verapamil antagonizes the increase of calcium in-
flux and its consequences and thus lowers the myo-
cardial oxygen requirement, resulting in an overall
improvement of the energy balance.
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It is also hoped that this effect can be achieved in
clinical tocolysis, in which Verapamil is admin-
istered in a maximum dose of 2 g/kg/min.
A second effect, a peripheral vascular dilatation, is
expected to lead to improved placental perfusion.
Furthermore, amelioration of the subjective com-
plaints associated withbeta-mimeticsisanticipated.
These include tremors, heat sensations, tendency
to break out in sweat, fear, and especially cardiac
palpitations with their extremely unpleasant effect
on the patient. The desired relaxation of the uteral
muscles by the calcium antagonist, äs demon-
strated in vitro, could not be clinically objectified.
The efficacy of Verapamil in doses of 2 Mg/kg/min
äs usual in tocolysis has not yet been established.
In the numerous clinical studies only subjective
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Fig. 1. Effect of adrenergics and Ca-antagonists on the
myocardium.
sensations and insensitive cardiovascular para-
meters of pregnant subjects could be monitored
during tocolysis. A basic investigation of the
desired calcium-antagonistic effect on the entire
cardiovascular System including the pulmonary
System is lacking.
In view of the increasing immber of reports ap-
pearing in the past few years of cardiopulmonary
complications, some fatal, we feel that a re-exami-
nation of the changes induced by betamimetics
and their antagonization by means of the calcium-
antagonist Verapamil is urgent.
The objective of the present work is to investigate
experimentally on dogs whether Verapamil in
doses of 2 Mg/kg/min has an itifluence on the
effects of beta-mimetics at all. The results will be
evaluated in light of prior clinical experience.
2 Material and methods
Nine mongrel German shqpherds with an average
body weight of 31 kg were anesthetized with
Fluanison and Fentanyl, correspondingtoO.lSmg/
kg Hypnorm®, given intramuscularly, and Metomi-
date, corresponding to 0.33 ml/kg Hypnodil®,
given intravenously. The anesthesia was continued
by slow drip intravenous infusion of 0.15 ml/kg/h
Metomidate. The animals were relaxed with 0.1
mg/kg Alcuroniumhy drochloride (Alloferin®) given
intravenously and subsequentiy with 0.1 mg/kg/h
by slow drip infusion. The controlled respiration
was carried out with atmospheric ir at constant
volume, the minute respiratory volume beirig set at
a paCO2 of 35 ± 3 mmHg.
Following suitable preliminary measurements the
animals were infused with Fenoterol* (0.06 μg/
kg/min) and from the 30th minute with Fenoterol
(0.06 μg/kg/min) and Verapamil (2 μ£ /̂ηιίη) for
a total of 90 min.
A constant record was kept of the fpllowing para-
meters:
1. a) The pulmonary arterial pressure (PAP) and
the pulmonary capillary wedge pressure
(PCWP), which correlates to the left atrial
pressure, by means of a 7 F $wan-Ganz-
thermal-dilution catheter located in the
arteria pulmonalis.
b) The arterial pressure by means of a fiber-
optical thermistor catheter, located in the
aorta ascendens (PAO)·
2. From the measured pressure parameters and the
cardiac Output the total pulmonary vascular
resistance (TPR) and the total systemic re-
sistance (TSR) were derived.
3. The pressure ratios in the left ventricle were
continuously monitored by means of an in*
inserted microtip manometer and from the
curves obtained cardiac inotropy quantities
were calculated with the aid of amicroprocessor.
These included maximum rate of pressure in-
crease (dp/dt^x), maximum acceleration of
pressure increase (d2p/dt2), intropy Index of
* P rtuisten®, C. H. BOEHRlNGER SOHN, Ingelheim/
Rhein, FRG.
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total myocardial oxygen consumption (Er).
4. By taking blood samples the hemoglobin con-
tent (Hb), oxygen partial pressure (p02), car-
bon dioxide partial pressure (pC02), sodium
(Na"1"), potassium (K*) and Chloride (Cf) concen-
trations, and the colloid osmotic pressure (COP)
in the arterial and venous blood were deter-
mined.
5. To rule out Ventilation disturbances, a con-
tinuous evaluation of oxygen consumption
(Vo2) and carbon dioxide output (VCO2) was
made.
6. Thanks to the development of the thermal dye
technique it is now possible to measure ac-
curately the fluid spaces in the lungs on a con-
tinuous basis, i.e. the intravascular and extra-
vascular spaces [19,22, 23,29].
As indicators indocyanine green and cold were
used. Folio wing an injection of ice-cold indo-
cyanine solution into the right atrium, the time-
concentration curves recorded in the aorta as-
cendens after passage through the lungs revealed
varying mean passage times, since the dye flowed
only through the intravascular space, the cold,
however, through both, the intravascular and the
extravascular space. From the indicator dilution
curves measured in the aortic arch, the cardiac
output, the extravascular flüid volüme in the
lungs (EW) and the total intravascular blood
volüme of the lungs (IVV) were calculated with
a microprocessor.
The experimental setup described permitted a con-
tinuous appraisal of the functional parameters of
the pulmonary and systemic hemodynamics, gas
exchange, Metabolie changes> and fluid displace-
ment in the lungs. It enabled us to obtain a com-
prehensive picture of the phärmacologicälly in-
duced physiological processes, Statistical valuation
of the effect by the üivestigated dfugs for all para-
meters was performed by calculating the Wilcoxon-
test for paired samples. Only variations compared
to the base line were of interest. The level of signi-
ficance was at = 0.05. The figures show the mean
value and the Standard error of the mean respec-
tively.
3 Results
Just shortly after infusion was commenced the
following changes were observed:
The cardiac frequency increased with the admini-
stration of Fenoterol from 119/min to a maximum
of 139/min (17%). The mean aortal pressure drop-
ped from 83 mmHg to a minimum of 56 mmHg,
while the pressure amplitude increased (Fig. 2). The
cardiac output rose from 116 ml/kg body weight/
min to a maximum of 158 ml/kg body weight/min.
The total systemic resistance (TSR) decreased by a
maximum of 44% (Fig. 3).
The changes are significant (p < 0.05).
After administration of Verapamil only the aortal
pressure continued to decrease further. The other
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Fig. 2. Changes in heart rate and aortal pressure in dogs
after administration of Fenoterol (0.06 Mg/kg/min) and
subsequently of Verapamil (2 Mg/kg/min); * = p < 0.05,
** = p<0.01.
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Fig. 3. Stroke volume, cardiac Output and total systemic
resistance in dogs after administration pf Fenoterol (0.06
Mg/kg/min) and subsequently of Verapamil (2
* = p < 0.05, **=p< 0.01.
Fig. 4. Behaviour of the inotropy parameters in dogs
after administration of Fenoterol (0.06 Mg/kg/min) and
subsequently of Verapamil (2 Mg/kg/min); * = p <0.05,
p < 0.01.**
The quantities measured in the left ventricle also
demonstrated beta-adrenergic-induced changes:
The maximum rate of pressure increase rose with
the administration of Fenoterol alone by a maxi-
mum of 34% and the maximum acceleration of
pressure increase by a maximum of 58%. The ino-
tropy index after BRETSCHNEIDER increased by a
maximum of 67% (Fig. 4). The total myocardial
oxygen consumption (Εχ) increased similarly
after administration of the beta-sympathicomi-
metic by a maximum of 25% (Fig. 5). These
changes were also significant and were in no way
meaningfully influenced by the addition of Vera-
pamil.
The mean pulmonary arterial pressure increased
under the influence of Fenoterol from 15.9 to
18.3 (15%) and reached a maximum of 19.9 mmHg
with the administration of Fenoterol + Verapamil.
By contrast, the pulmonary capillary wedge press-
ure remained constant at 8.61 mmHg throughout
the entire experiment. The slight increase in total
pulmonary resistance was not significant (Fig. 6),
The extravascular fluid volume in the lungs incre-
ased after just 20 minutes form 8.9 ml/kg body
weight to 12.7 ml/kg body weight (42%), The
fluid displacement shifted in favour of the inter-
stice. In accordance with these findings the intra-
vascular fluid volume decreased (Fig. 7a). The total
fluid volume remained nchanged throughout tiie
experiment at an average of 22.5 ml/kg body
weight (Fig. 7b). Here too, the administration of
Verapamil brought no significant iurther changes.
J, Perinat. Med. 9 (1981)
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Fig. 5. Total oxygen consumption of the left ventricle in dogs after administration of Fenoterol (0.06 Mg/kg/min) and
subsequently of Verapamil (2 Mg/kg/min); * = p < 0.05, ** = p < 0.01.
The arterial blood gas analyses showed a drop in
the oxygen partial pressure form 84.3 mmHg to
80.9 mmHg and in the oxygen Saturation from
92.7% to 87.8%, äs well äs an increase in the C02-
partial pressure from 37.7 mmHg to a maximum
of 47.5 mmHg (Fig. 8).
In addition, a highly significant drop in the arterial
pH from 7.42 to 7.25, in the Standard bicarbonate
from 23.4 mval/1 to 19.1 mval/1, and in the base
excess from + 0.2 mval/1 to - 7 mval/1 was ob-
served (Fig. 9).
The changes in the venous system were even more
pronounced. Here the pH showed a highly signi-
ficant drop from 7.4 to 7.18, the HCOä from 27.0
mval/1 to 20.1 mval/1, and the base excess from
+ 2.8 mval/1 to - 7.5 mval/1 (Fig. 10). '
The venous blood gases analyses revealed a strong
increase in the 02partial pressure from 38.8 mmHg
to 57.3 mmHg and in the venous C02 partial press-
ure from 45.2 mmHg to 58.1 mmHg (Fig. 11).
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The oxygen absorption in creasedat constant respir-
atory volume and constant respiratory rate from
159 ml/min to 183 ml/min (15%).
The CÜ2 Output increased even more strongly from
116 ml/min to 144 ml/min (24%) with a conse-
quent increase of the respiratory quotient (RQ)
from a physiological value of 0.75 to 0.83 (Fig. 12).
The other changes in the above parameters after
the administration of Verapamil were not signi-
ficant.
The colloid osmotic pressure in the plasma re-
mained constant at a mean value of 18.4 mmHg.
The serum potassium decreased only negligibly
from 3.22 mval/1 to 2.65 mval/1, whereas the
serum sodium remained unchanged at about 148
mval/1 (Fig. 13).
With exception of the aortal pressure, which con-
tinued to drop after administration of Verapamil,
none of the measured parameters was significantly
further influenced by the calcium-antagonist Vera-
240 Strigl et al., Verapamil in tocolysis
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Fig. 6. Parameters of the pulmonary'circulatory System in
dogs after administration of Fenoterol (0.06 Mg/kg/min)
and subsequently of Verapamil (2 Mg/kg/min);*=p<0.05,
p<0.01.**
pamil after previous administration of the beta-
mimetic Fenoterol.
4 Discussion
The effectiveness and the mechanism underlying
the effect of the calcium antagonist Verapamil
are known and are indisputable. They have been
demonstrated in numerous well-founded works,
in part on isolated preparations and in part on
animals äs well äs on sick and healthy people [11,
15, 16, 24, 25, 26,27]. FLECKENSTEIN [12] reve-
aled the mechanism of the cardiotoxic effect of
adrenergics and the possibility of antagonizing
this effect with Verapamil (Fig. 1).
As the prototype of beti-mimetics in earlier ex-
periments, they used Isoproterenol. It has been
shown that adrenergics lead to infarct4ike lesions
[33] with the clinical picture of catecholamin-
myocarditis arising from hypoxiai [4, 37]. These
myocardial alterations, also found after an over-
dose of adrenergics and in pheochromocytoma
[4], have gained importance in obstetrics ever
since reports have been appearing in the past few
years not only of serious pulmonary complications
in the form of pulmonary edema [l, 2, 5, 8, 13,
20, 39, 43, 45, 46], but also of severe myocardial
damage in tocolysis with various beta-sympathico-
mimetics [2,6,7,31].
Also, infantile myocardiopathy after protracted
tocolysis has been observed. A cörrelation be-
tween the therapy with betä-mimetics and the
cardiac damage seems at least plausible [32, 40,
42]. Thus, interest became centered on the effects
of the calcium-antagonist Verapamil administered
in tocolysis. Whereas at first only an improvement
of the subjective complaints after administration
of beta-mimetics was hoped for, it is now the
question of a demonstrable effect on the cardovas-
cular System that raises interest. The pulmonary
circulatory system must be included in these con-
siderations.
The cardioprotective effect of Verapamil is asso-
ciated with a negative inotropic and negative
chronotropic effect. It is precisely these effects
that have been least researched in tocolysis. In our
experiments the contractility parameters and con-
sequentiy also the myocardial oxygen require-
ment changed after administration of Fenoterol, äs
is to be expected from a beta-mimetic.
The contractility underwent an enormous increase
äs did the oxygen consumption, the end effect of
which must be a deterioration of the energy
balance. The administration of Verapamil at the
dosage rate of 2 Mg/kg/min had no influence on
this process. Thus a cardioprotective effect on the
myocardium could not be proved.
That the mean arterial pressure continued to drop
slightly after administration of Verapamil was
chiefly due to the lowered diastolic pressure.
Whether this effect is to be attributed to Feno-
J. Perinat. M ed. 9 (1981)
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Fig. 7a. Intrapulmonary fluid shifts in dogs after administration of Fenoterol (0.06 Mg/kg/min) and subsequently of
Veiapamil (2 /ig/kg/min); * = p < 0.05, ** = p < 0.01.










*^~~r \j } ί *
• ι ι · · · · * * ·
VW 10 20 30 40 50 60 70 80 90 min
N = 8 8 8 8 8 9 9 9 9 9
- For
IM Verrapamil
Fig. 7b. Total intrapulmonary liquid balance in dogs after administration of Fenoterol (0.06 Mg/kg/min) and sub-
sequently of Verapamil (2 Mg/kg/min).




































Fig. 8. Behaviour of arterial blood gases in dogs after ad-
ministration of Fenoterol (0.06 Mg/kg/min) and subse-







































Fig. 9. Arterial acid-base-status in dogs after administra-
tion of Fenoterol (0.06 Mg/kg/min) and subsequently of
Verapamil (2 Mg/kg/min); * = p < 0.05, ** = p < 0.01.
terol or to Verapamil cannot be stated. A Vera-
pamil effect, however, seems unlikely, in view of
the fact, that no other parameter of the systemic
and pulmonary drculatory System underwent
furtherchange.
The metabolic acidosis known to occur after ad-
ministration of Fenoterol [21, 41] was also en-
countered in our investigations. It reacted äs little
to the administration of Verapamil äs did the
changes in the Ventilation and the blood gases.
The explanation for the ineffectiveness of the
calcium antagonist Verapamil lies in the low dose
of 2 Mg/kg/min. The desired shift of the functional
operating curves of the heart and the circulatory
effect of Verapamil can only be achieved with
doses far higher than those used in tocolysis. In
these earlier studies an effect was demonstrated in
dogs only after a dose of 200 Mg/kg/min, given äs a
single injection, and in humans only after serum
concentrations of 200 Mg/ml were reached [11,15,
16, 24, 25], HAAS and RASCHAK [16] also repor-
ted that in general extremely high doses of the cal-
cium antagonist are required to obtain the negative
inotropic effect. The reason for this is the rapid
biotransformation of the active substance Verapa-
mil into ineffective or only weakly effective meta-
bolites [34], Our own studies [38] have revealed
that the average serum concentration of the
mother after administration of Verapamil at a
dosage rate of 2 Mg/kg/min was 19.3 ± 3 ng/ml.
Since fluid displacements in the lungs up to the
severity of manifest pulmonary edema after ad-
ministration of adrenergics is due at least in part
to hemodynamic factors [3, 10, 36], it comes äs
no surprise that the administration of Verapamil
has no influence on the fluid displacement from
the intravascular to the extravascular space in-
duced by Fenoterol.
In accordance with our findings, no change in the
objective cardiovascular parämeters in tocolysis
with beta-mimetics attributable to the administra-
tion of Verapamil could be clinically established
[14, 17, 28, 30], The researches had restricted
themselves for the most part to measuring the
J.Perinat. Med.9 (1981)

































Fig. 10. Venous acid-base-balance in dogs after administra-
tion of Fenoterol (0.06 Mg/kg/min) and subsequently of


























Fig. 11. Behaviour of venous blood gases in dogs after ad-
ministration of Fenoterol (0.06 Mg/kg/min) and subse-
quently of Verapamü (2 Mg/kg/min); * = p<0.05,
**=p<O.OL
Parameters of the systemic circulatory System. In a
recent study HOFSTETTER [18] showed the in-
effectiveness of the calcium antagonist in this
dosage by using echocardiography to measure the
inotropy. Objective improvements in the cardio-
vascular load achieved with Verapamü during
tocolysis that have been determined with im-
pedance measürements [35] must be viewed
with scepticism owing to the inherent errors of the
method. The elimination or manifest improvement
of the side effects of beta-mimetics with Vera-
pamil described by many authors are difficult to
objectify.
The cardioprotectiye effect of Verapamil in a
Fenoterol bath demonstrated in vitro [44] may
result from the lack of metabolic decomposition
and the resulting higher concentrations.
S Conclusions
1. Fenoterol at a dosage rate of 0.06 Mg/kg/min
induces in dogs the cardiovascular and metabolic
changes expected from the beta-sympathicomi-
metic. Besides this it causes significant intra-
pulmonary fluid shifts from the intravascular
space to the interstice.
2. Verapamil in the dosage usual in clinical tocolysis
of 2 g/kg/Inin has no influence on the changes
induced by the beta-mimetic drug which are de-
monstrated in the present work. These results
agree well with previous clinical experiments.
3. In order to achieve an effect the Verapamil
dosage must be increased multifold, which hard-
ly seems feasible in view of the cardiodepression
and peripheral dilatation this would entail.
4. Since beta-sympathicomometics in labor sup-
pression cannot be dispensed with at this time,
further investigations will be necessary to find a
substance that antagonizes the cardiovascular
side effects in a way that can be objectified.
J. Perinat.Med.9(1981)
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Fig. 12. Behaviour of the paiameters of energy transfor-
mation in dogs after administration of Fenoterol (0.06
Mg/kg/min) and subsequently of Verapamil (2 Mg/kg/min);
* =p < 0.05, ** = p < 0.01.
Fig. 13. Behaviour of the colloid osmotic pressure, plasma
sodium and potassium in dogs after administration of
Fenoterol (0.06 Mg/kg/min) and subsequently of Vera-
pamil (2 Mg/kg/min).
Summary
In tocolysis with beta-sympathicomimetics Verapamil is
administered universally to reduce the subjective and ob-
jective cardiovascular side effects. The efficacy of the
calcium-antagonist has not yet been substantiated. This
has now re-emerged s an important issue due to the in-
creasing occurrance of cardiopulmonary complications in
tocolysis, some fatal.
Nine mongrel German shepherds were anesthetized and
relaxed, and their breathing was controlled at constant vol-
ume. After Infusion of Fenoterol (0.06 Mg/kg/min) and sub-
sequent administration of Verapamil (2 Mg/kg/min) a con-
tinuous record was made of the parameters of the pulmo-
nary and systemic circulatory Systems, the cardiac dynam-
ics, the acid-base balance, the blood gases with O2 absorp-
J. Perinat. Med. 9 (1981)
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tion and CO2 Output, electrolytes and the colloid osmotic
pressure. Furthermore, the intrapulmonary fluid volumes
in the vascular System and the interstice were measured.
During Infusion with Fenoterol the changes expected
from a beta-adrenergic were observed in the form of a
hyperkinetic cardiac Situation, metabolic acidosis and in-
creased exchange of gases. Also pronounced fluid shifts
in the lungs occuned from the intravascular space to the
interstice.
Subsequent administration of the calcium antagonist
showed no influence on the beta-mimetic-induced changes
demonstrated in the present work.
The results agree with previous clinical investigations. Ac-
cording to the known dosage curve, the dosage of Vera-
pamil would have to be increased multifold to achieve an
effect, which is hardly possible due to the cardiodepres-
sion and peripheral circulation drop with hypotension
that this would entail.
The administration of Verapamil in tocolysis no longer
appears expedient.
Keywords: Betamimetic drugs, calcium antagonists, myocardiopathy, pulmonary edema, tocolysis.
Zusammenfassung
Hat der Zusatz des Kalziumantagonisten Verapamil bei
der Tokolyse mit Betasympathikomimetika noch einen
Sinn?
Bei der Tokolyse mit Betasymathikomimetika wird zur
Verringerung der subjektiven und objektiven kardiovasku-
lären Nebenwirkungen weltweit Verapamil zugesetzt.
Die Wirksamkeit des Kalziumantagonisten ist bisher nicht
gesichert. Ihr kommt jedoch nach immer häufiger auftre-
tenden, teilweise letal verlaufenden kardiopulmonalen
Zwischenfällen bei der Tokolyse wieder vermehrt Bedeu-
tung zu.
9 Bastardschäferhunde wurden narkotisiert, relaxiert und
volumenkonstant kontrolliert beatmet. Nach Infusion von
Fenoterol (0.06 Mg/kg/min) und späterem Zusatz von Vera-
pamfl (2 Mg/kg/min) konnten laufend die Parameter des
großen und kleinen Kreislaufs, der Herzdynamik, des
Säure-Basen-Haushalts sowie die Blutgase mit (^-Auf-
nahme und CXVAbgabe, Elektrolyte und der Kolloid-
osmotische Druck bestimmt werden. Außerdem wurden
die intrapulmonaren Flüssigkeitsvolumina im Gefäßsystem
und im Interstitium gemessen.
Während der Infusion von Fenoterol zeigten sich die für
ein Betaadrenergikum zu erwartenden Veränderungen im
Sinne einer hyperkinetischen kardialen Situation, eine
metabolische Azidose und ein verstärkter Gasaustausch.
Weiter kam es zu einer deutlichen Flüssigkeitsverschie-
bung in der Lunge vom intravasalen Raum zum Intersti-
tium. Der spätere Zusatz des Kalziumantagonisten zeigte
keinen Einfluß auf die in dieser Arbeit nachgewiesenen,
durch das Betamimetikum bedingten Veränderungen.
Die Ergebnisse entsprechen den bisherigen klinischen Un-
tersuchungen. Nach den bekannten Dosisleistungskurven
müßte zum Erreichen einer Wirkung die Dosis von Vera-
pamil auf ein Vielfaches erhöht werden. Dies ist wegen
der zu erwartenden kardialen Depression und dem peri-
pheren Kreislaufabfall mit Hypotension schlecht möglich.
Der Zusatz von Verapamil bei der Tokolyse mit Beta-
sympathikomimetika erscheint nicht mehr sinnvoll.
Schlüsselwörter: Betamimetika, Kalziumantagonisten, Kardiomyopathie, Lungenödem, Tokolyse.
Resume
L'administration de Verapamil, antagpniste du calcium,
lors de la tocolyse par les betamimetiques, garde-t-elle
encore une signification.
Lors de la tocolyse par beta-mimetiques, toiit le monde
administre du Verapamil afin de reduire les effets secon-
daires cardio-vasculaires subjectifs et objectifs. L'efficacite
de cet antagoniste du calcium n'a cependant pas ete
etablie.
Ce point resurgit maintenant de fagon aigue a cause de la
survenue croissante de complications cardio-pülmpnaires,
dont quelques unes fatales, au cours de la tocolyse.
9 bergers-allemands batards ont ete anesthesies et leur
respiration a ete controlee a volume constant. Apres
perfusion de Fenoterol (0,06 Mg/Kg/min) et administration
secondaire de Verapamil (2 Mg/Kg/min),unenregistrement
continue a ete r&lise des parametres des Systeme circula-
toires pulmonaires et systematiques, de la dynamique
cardiaque, de l'equilibre acido-basique, des gaz du sang
avec la consommation d'Oj et l'elimination de CQi, des
electrolytes et de la pression osmotique. En outre, les
volumes liquides intra-pulmonaires dans le Systeme vascu-
laire et dans l'espace interstitiel ont ete mesures.
Pendant la perfusion de Fenoterol, on a observe les modi-
fications attendues d'un beta-adrenergique sous Taspect
d'une activite cardiaque hypercinetique, d'une acidose
metabolique et d'echanges gazeux augmentes. Se produi-
skent egalement des modifications liquidiennes impor-
tantes de l'espace intravasculaire vers l'espace interstitiel
pulmonaire. L'administration secondaire de l'antagoniste
du calcium n'a pas montre d'influence demontree dans ce
travail sur les modifications induites par les beta-mimeti-
ques.
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Les resultats concordent avec les explorations cliniques de la circulation peripherique avec hypotension que cela
ant6rieures. Selon la cinetique du dosage habituel, la entrainerait.
posologie du Verapamil devrait etre augmentee plusieurs L'administration de Verapamf lors de la tocolyse avec
fois pour exercer une action, ce qui est difficilement pos- betamimetiques n'apparait plus comme opportune.
sible du fait de la depression cardiaque et de la diminution
Mots-cles: Antagonistes du calcium, betamimetiques, myocardiopathie, oedeme pulmonaire, tocolyse.
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